Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imatinib + aluminum hydroxide + magnesium hydroxide
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug combination refers to the co-administration of imatinib mesylate (Gleevec) and magnesium-aluminum-based antacids (specifically Maalox), which was investigated in a Phase 1 clinical trial (NCT00446316) conducted by the University of Pittsburgh. Imatinib is a small molecule tyrosine kinase inhibitor that targets several proteins including BCR-ABL, c-KIT, and platelet-derived growth factor receptors (PDGFR). It is primarily indicated for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The study evaluated the pharmacokinetic interaction between imatinib and antacids containing aluminum hydroxide and magnesium hydroxide to determine if neutralizing gastric acid alters the absorption of imatinib, which is critical for maintaining therapeutic drug concentrations and preventing treatment resistance.
- Brand names
- GleevecMaalox
- Other names
- imatinib mesylatealuminum hydroxidemagnesium hydroxideMg-Al-based antacids
02
Targets
PDGFR (PDGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on imatinib + aluminum hydroxide + magnesium hydroxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imatinib + aluminum hydroxide + magnesium hydroxide.